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Abstract
The prevalence of anxiety disorders is known to be increasing among children 
and adolescents and often co-exist with another psychiatric disorder. There is some 
evidence that anxiety disorders in nonwestern countries have the same comorbid-
ity patterns as in other world regions and may have similar predictors including 
age and gender. However, more evidence from different countries is needed.  The 
major goal of the study was to evaluate the prevalence of anxiety disorders in 
a clinical setting and to describe the comorbidity patterns and predictors. We 
conducted a retrospective study on the admitted patients in the Clinic of Pediatric 
Psychiatry from Cluj-Napoca, Romania, between January 2017 and December 
2017. A clinical sample of 2471 patients aged between 3 and 18 years with psychi-
atric disorders, assessed and/or treated in the clinic, was included into the study. 
About 9.88% patients (N = 244) of the clinical sample were diagnosed with an 
anxiety disorder as a primary diagnosis. About 79.5% of the selected sample had a 
comorbid disorder and 34.4% had an anxiety or mood comorbidity. Preference in 
treatment was nonpharmachological and, according to the degree of severity, SSRI 
medication. Our results underline the significant prevalence of anxiety disorders 
and the high rate of comorbidities.
Keywords: anxiety disorders, prevalence, comorbidities, children and adolescents, 
pharmacological treatment
1. Introduction
1.1 Diagnostic systems
Anxiety disorders (ADs) are one of the most important conditions in child and 
adolescent psychiatry with a heterogeneous spectrum of clinical manifestations and 
variable levels of severity. ADs are commonly found at all levels of mental health 
services and involve the use of large resources for the appropriate assessment and 
therapeutic approach.
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Anxiety disorders (ADs) are classified in DSM-5 (APA) [1] or ICD-10 (WHO) 
[2] diagnostic systems. Although developmental pathway features or a variety of 
other factors can significantly influence clinical presentation, both classification 
systems describe common clinical features for AD [3] and use roughly the same 
diagnosis criteria for children and adolescents as compared to adults. ICD-10, in 
contrast to DSM-5, uses several separate diagnostic codes for children. The new 
proposed disorder categories in ICD-11 are largely the same as those in the equiva-
lent section of DSM-5 and recognize that the same disorders occur across the life 
span with developmentally distinct presentations [4]. Therefore, diagnoses in ICD 
are made based on essential features, with the expectation that the clinicians will 
use their clinical judgment on exact symptom counts and duration in a manner that 
is consistent with the diagnostic guidance provided [5]. Although this descriptive 
diagnosis criteria facilitated the development of diagnostic instruments for AD 
assessment [6–10], clinicians should be aware of their limitations, particularly 
related to developmental issues in obtaining self-reports from children and adoles-
cents [11]. Due to these considerations, the core diagnostic criteria might present 
differently in the young, requiring special assessment strategies.
1.2 Prevalence
Mental disorders affect a significant number of children and adolescents world-
wide [12]. Among the children and adolescent psychiatric disorders, ADs are a rep-
resentative category. Prevalence rates reported in studies are varying considerably 
sometimes, depending on the sample, assessment methods, the assessed period, or 
study design, between 6.5 [12] and 8.3% [13] and up to 27% [14]. In a meta-analysis 
of multiple data sets, Costello et al. have found the prevalence of 10.2% for any AD, 
5.4% for specific phobia (SPEC), 3.6% for social phobia (SOC), 2.6% for separation 
anxiety disorder (SAD), 1.7% for generalized anxiety disorder (GAD), and 0.8% 
for panic disorder (PD) [15]. In the National Comorbidity Survey Replication and 
Adolescent Supplement, Kessler et al. reported a lifetime prevalence of any anxi-
ety disorders of 32.4%, for the ages of 3–17 [16]. Spence et al.’s results are slightly 
different, with reported prevalence rates of 2.3% for social phobia (SOC), 4.3% for 
separation anxiety (SAD), and 2.2% for generalized anxiety disorder (GAD) [17]. 
Previous studies reported similar prevalence rates in diverse cultures [18–20].
In terms of onset age, Merikangas et al. found a prevalence of 31.4% for the age 
group of 13–14 years, 32.1% for the age group of 15–16 years, and 32.3% for the age 
group of 17–18 years, with particularly high rates of specific phobia (SPEC) [13]. 
Generalized anxiety disorder and social anxiety disorder are among the most com-
mon AD in youth [21]. Panic disorder is rare and occurs in adolescents rather than 
in young children [15, 21]. Findings from different studies have demonstrated that, 
in the general population, anxiety symptoms first decrease during early adolescence 
and subsequently increase from middle to late adolescence [22]. Separation anxiety 
disorder and specific phobias tend to emerge and predominate during childhood, 
whereas the initial onset of generalized anxiety disorder, panic disorder, and social 
anxiety disorder most often occurs during adolescence [16, 23].
The literature describes the theory on distinct latent developmental trajectories 
for different anxiety disorder symptoms, emphasizing the importance of examining 
separate anxiety dimensions rather than considering anxiety as a general construct. 
For example, girls were significantly more likely than boys to be in numerous latent 
generalized anxiety disorder symptom trajectory classes, including those distin-
guished by very high initial symptoms that decrease rapidly, high initial symptoms 
that decrease less markedly over time, and moderate initial symptoms that decrease 
slightly over time [24]. The results from Crocetti et al.’s study regarding latent 
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growth trajectory classes found that adolescent population was best typified by a 
low-anxiety class, characterized by a low initial anxiety level that decreased over 
time and a high-anxiety class characterized by a higher initial anxiety level that 
increased over time [25]. In a 5-year study of Dutch, youth aged between 10 and 
12 years at baseline, generalized anxiety disorder, panic disorder, and social anxiety 
disorder symptoms slightly decreased and then leveled off from early to middle 
adolescence, followed by a slight increase in generalized anxiety disorder and 
social anxiety disorder symptoms during middle adolescence and in panic disorder 
symptoms during late adolescence [22, 26]. Similar results have been reported by 
recent studies [24, 27].
There are mixed data regarding the differential gender prevalence rates of 
anxiety. Similar to gender ratio for adults, girls tend to have more of all subtypes 
of anxiety disorders, but there is no significant difference between boys and girls 
in the mean age at onset of anxiety [28]. Some studies showed that girls have a 
higher risk to develop AD [13, 16], are more affected [13, 24], and report higher 
cross-sectional anxiety symptom levels [29–31], and these differences remain stable 
during adolescence [20].
1.3 Comorbidities
Generally, in child and adolescent psychiatry, the comorbidities are the rule, 
and anxiety disorders fit into this pattern. In the clinical practice, AD comorbidities 
in internalization symptom area are commonly identified and closely monitored 
compared with the externalization symptoms. However, there are very few papers 
focused on the comorbidity between specific anxiety disorders and other psychiat-
ric diagnoses.
Comorbidity occurs frequently, both within the anxiety disorders and also 
with other psychiatric disorders. At least one third of the children and adolescents 
diagnosed with anxiety disorders meet the criteria for two or more anxiety disor-
ders [32]. Children with a primary anxiety disorder were significantly more likely 
to be diagnosed with separation anxiety disorder than adolescents. Adolescents 
with a primary anxiety disorder received more frequently a primary diagnosis 
of social anxiety disorder, mood disorders, and irregular school attendance [33]. 
Anxiety disorders are associated with all the other major classes of disorders, 
including mood disorders, disruptive behaviors, ADHD, eating disorders, and 
substance use disorders [19, 28, 34–36]. Merikangas et al. reported in their 
national survey among adolescents aged 13–18 years that the anxiety disorders 
were the most common condition (31.9%), with approximately 40% of those with 
one class of disorder also meeting criteria for another class of lifetime disorder 
[13]. Costello et al. found that comorbidity with other psychiatric disorders was 
common, ranging from 53% of the generalized anxiety disorder cases to 100% of 
specific phobia cases. The most common type of comorbidity with non-anxiety 
disorders was with depression [15, 20, 37, 38]. Adolescents with high levels of 
depressive symptoms experienced less significant decline over time in symp-
toms of physical, social, and separation anxiety [30]. The Oregon Adolescent 
Depression Study, looking at lifetime diagnoses, revealed that depression was sig-
nificantly associated with each of the anxiety disorders except obsessive-compul-
sive disorder. Other lifetime associations found were ADHD with specific phobia 
and bipolar disorder with separation anxiety in males [39]. In preschool children, 
Sterba et al. used confirmatory factor analysis to show that the best-fitting model 
for the emotional disorders had three factors (social phobia, separation anxiety, 
and a factor that combined GAD and depression) with significant correlations 
between these three factors and conduct disorder, oppositional disorder, and 
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ADHD [40–42]. Social, separation, and generalized anxiety disorders in young 
people are relatively common and with a high level of comorbidity. All three ADs 
have a relatively high level of comorbidity with depression and a moderate degree 
of comorbidity with ADHD [17].
The major goal of the present study was to assess the prevalence of anxiety 
disorders among children and adolescents in a clinical setting and to describe the 
comorbidity and pharmacological treatment patterns.
2. Method
2.1 Participant selection
We conducted a retrospective study on the admitted patients in the Clinic of 
Pediatric Psychiatry from Cluj-Napoca, Romania, between January and December 
2017. A clinical sample of 2471 patients aged between 3 and 18 years, with differ-
ent psychiatric disorders, assessed and/or treated in the clinic, was included in the 
study. 9.88% (N = 244) of the clinical sample were children and adolescents diag-
nosed with an anxiety disorder via the 10th revision of the International Statistical 
Classification of Diseases and Related Health Problems (ICD 10)-based clinical 
interviews. Participants were grouped according to the “primary” diagnosis, the 
primary diagnosis referring to the severity of current diagnoses and not the order 
of onset (the reason for admission). In accordance with the removal of OCD and 
PTSD from the broad anxiety disorders category in DSM-5 (American Psychiatric 
Association, 2013), the patients with a primary diagnosis of OCD and PTSD were 
excluded from this study.
We included in the study: boys or girls aged 3–18 with a diagnosis of anxiety 
disorders (agoraphobia; social phobias; specific phobias; other/unspecified phobic 
anxiety disorders; panic disorder; generalized anxiety disorder; mixed anxiety 
and depressive disorder; other mixed, specified, or unspecified anxiety disorders; 
separation anxiety disorder of childhood; social anxiety disorder of childhood), 
according to ICD-10 international diagnosis criteria, admitted for assessment or 
treatment; agreement (children/adolescent and caregiver) to participate after the 
purpose and protocol of the study was explained. We excluded from the study: 
children and adolescents admitted with other diagnosis than anxiety disorders and 
the patients receiving services in outpatient settings.
Data were collected from the patients’ medical records (sociodemographic, 
clinical evaluations, and treatment recommendations). From the total of the 2471 
patients selected, 244 children and adolescents were diagnosed with a type of 
anxiety disorder as a primary diagnosis. The patients come from all the countries 
and are diverse in terms of socioeconomic status. The mean age of participants 
was 12.75 (SD = 3.90), their age ranging from 3 to 18 years. All the participants 
were Caucasian. Data were used ensuring the privacy and subject’s identity 
protection.
2.2 Statistical analysis
The Statistical Program for Social Sciences (SPSS) v. 17 was used for data analy-
sis. To describe and assess the selected population, we used univariate statistical 
analysis (mean, standard deviation, frequencies). Pearson chi-square test was used 
to verify the association among categorical variables, and t-test was used to com-
pare the mean age. The level of significance was set at 5%, and a confidence interval 
(CI) of 95% was used in all tests.
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2.3 Results
Two hundred forty-four patients with a primary diagnosis of anxiety disorder 
were included in the study of which 130 (53.3%) were males and 114 (46.7%) were 
females. The boy-girl ratio was 1.14:1. The mean age of boys and girls differs signifi-
cantly (mean (SD) boys = 12.02 (4.08), girls = 13.60 (3.52), t = −3.24, p = 0.001).
2.3.1 Primary disorder prevalence
We analized the prevalence data for all anxiety disorder diagnosis of the patients 
included in the study, with current ICD 10 principal diagnosis are presented. As 
seen in Table 1, the most commonly occurring diagnosis were generalized anxiety 
disorder (GAD) 35.7% of the sample, social phobias (SOC) 12.3%, mixed anxiety 
and depressive (MAD) disorder 11.5%, other specified anxiety disorders (OSA) 
9%, and separation anxiety disorder (SAD) of childhood 8.6%. The other anxiety 
disorders were less represented in our sample: specific phobias (SPEC) 6.1%, other 
phobic anxiety disorders (NOS) 4.9%, anxiety disorder, unspecified (ADU) 3.7%, 
panic disorder (PD) 3.3%, other mixed anxiety disorders (OMAD) 1.6%, phobic 
anxiety disorder, unspecified (UNS) 0.8%, and social anxiety disorder of child-
hood (SADC) 0.8%. About 20.5% of the sample (N = 50) had only 1 diagnosis at 
admission, 46.7% (N = 114) had 2 diagnoses, and 32.8% (N = 80) had 3 or more 
clinical diagnoses. Comorbidity is defined as having two or more co-occurring 
current diagnoses. Table 1 presents the prevalence of the additional diagnosis for 
the participants grouped by the principal diagnosis. 34.4% of the participants had 
a diagnosis of anxiety or depressive disorder in addition to their principal anxiety 
disorder diagnosis. The other frequent comorbidities were attention deficit hyper-
activity disorder (ADHD) (28.7%) and autism spectrum disorder (ASD) (8.6%).
2.3.2 Age and gender
The participants were divided into two groups by age: children (N = 88; 
3–11 years of age) and adolescents (N = 156; 12–18 years of age). Among partici-
pants who met diagnostic criteria for the targeted anxiety disorders (N = 244), 
adolescents were significantly more likely to receive a principal diagnosis of GAD 
than children (39.7 vs. 28.4%, chi-square = 13.11, p < 0.001) or MAD (13.5 vs. 
8%, chi-square = 9.33, p = 0.02). The prevalences of generalized anxiety disorder 
(GAD) and mixed anxiety and depressive (MAD) disorder were found higher in 
adolescents than in children (Table 1), but with a higher prevalence in adolescent 
girls, the proportion of boys diagnosed with GAD and MAD being relatively stable 
with age. Children were more likely to receive a principal diagnosis of SPEC than 
adolescents (11.4 vs. 3.2%, chi-square = 3.75, p = 0.05). For specific phobias (SPEC), 
the prevalence was higher in children than in adolescents, but while the proportion 
of boys remained relatively stable, the diagnosis wasn’t present in adolescent girls.
No significant differences by age were found for the other anxiety disorders. 
The odds for boys to have a primary diagnosis of anxiety disorder was 2.63 (95% CI 
1.52, 4.55), with a risk of 1.87 in children (95% CI 1.29, 2.72) and 0.71 in adolescents 
(95% CI 0.59, 0.86).
Among the participants that met the diagnosis criteria for at least one comorbid-
ity (N = 194), adolescents were more likely than children to meet criteria for other 
anxiety disorder (14.7 vs. 13.6%, chi-square = 5.41; p = 0.02) or MDD (25.6 vs. 
10.2%, chi-square = 5.49; p = 0.019). When looking at the age and gender trends 
for these comorbidities, we can observe some differences. While for the comorbid-
ity with other anxiety disorder, the prevalence in adolescent boys is decreasing; in 
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Children Adolescents Statistic
Male (N = 60) Female (N = 28) All (N = 88) Male (N = 70) Female (N = 86) All (N = 156) (Children vs. 
adolescents)
Anxiety disorders F40.0—(AG) 1 (1.7%) 1 (3.6%) 2 2 (2.9%) 0 2 χ²(1) = 1.33, p = .24
F40.1—(SOC) 7 (11.7%) 3 (10.7%) 10 13 (18.6%) 7 (8.1%) 20 χ²(1) = 0.75, p = .78
F40.2—(SPEC) 5 (8.3%) 5 (17.9%) 10 5 (7.1%) 0 5 χ2 (1) = 3.75, p = .05
F40.8—(NOS) 3 (5%) 4 (14.3%) 7 2 (2.9%) 3 (3.5%) 5 χ2(1) = 0.01, p = .92
F40.9—(UNS) 0 1 (3.6%) 1 0 1 (1.2%) 1 —
F41.0—(PD) 1 (1.7%) 0 1 3 (4.3%) 4 (4.7%) 7 χ2(1) = 1.14, p = .28
F41.1—(GAD) 20 (33.3%) 5 (17.9%) 25 23 (32.9%) 39 (45.3%) 62 χ2(1) = 13.11, p = .000
F41.2—(MAD) 7 (11.7%) 0 7 7 (10%) 14 (16.3%) 21 χ2(1) = 9.33, p = .002
F41.3—(OMAD) 0 1 (3.6%) 1 0 3 (3.5%) 3 —
F41.8—(OSA) 3 (5%) 0 3 8 (11.4%) 11 (12.8%) 19 χ2(1) = 3.47, p = .06
F41.9—(ADU) 2 (3.3%) 0 2 5 (7.1%) 2 (2.3%) 7 χ2(1) = 0.73, p = .39
F93.0—(SAD) 11 (18.3%) 8 19 1 (1.4%) 1 (1.7%) 2 χ2(1) = 0.046, p = .83
F93.2—(SADC) 0 0 0 1 (1.4%) 1 (1.7%) 2 —
Comorbid anxiety 
disorders
8 (13.3%) 4 (14.3%) 12 6 (8.6%) 17 (19.8%) 23 χ2(1) = 5.41, p = .02
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Children Adolescents Statistic
Male (N = 60) Female (N = 28) All (N = 88) Male (N = 70) Female (N = 86) All (N = 156) (Children vs. 
adolescents)
Mood disorder MDD 7 (11.7%) 2 (7.1%) 9 14 (20%) 26 (30.2%) 40 χ2(1) = 5.49, p = .019
Other ADHD 31 (51.7%) 13 (46.4%) 44 18 (25.7%) 8 (9.3%) 26 χ2(1) = 0.012, p = .91
ASD 6 (10%) 4 (14.3%) 10 10 (14.3%) 1 (1.2%) 11 χ2(1) = 2.75, p = .097
MR 3 (5%) 1 (3.6%) 4 4 (5.7%) 1 (1.2%) 5 —
OCD 0 1 (3.6%) 1 1 (1.4%) 2 (2.3%) 3 —
Conduct disorder 0 0 0 1 (1.4%) 1 (1.2%) 2 —
ODD 1 (1.7%) 0 1 0 1 (1.2%) 1 —
ATP 0 0 0 0 1 (1.2%) 1
No disorder 4 (6.7%) 3 (10.7%) 7 15 (21.4%) 28 (32.6%) 43 χ2(1) = 1.26, p = .261
Note: AG = agoraphobia; SOC = social phobias; SPEC = specific phobias; NOS = other phobic anxiety disorders; UNS = phobic anxiety disorder, unspecified; PD = panic disorder; GAD = generalized anxiety 
disorder; MAD = mixed anxiety and depressive disorder; OMAD = other mixed anxiety disorders; OSA = other specified anxiety disorders; ADU = anxiety disorder, unspecified; SAD = separation anxiety 
disorder of childhood; SADC = social anxiety disorder of childhood; OAD = other anxiety disorders; MDD = major depressive disorder; ADHD = attention deficit hyperactivity disorder; CD = conduct disorder; 
ASD = autism spectrum disorder; MR = mental retardation; OCD = obsessive-compulsive disorder; ODD = oppositional defiant disorder; ATP = acute and transient psychotic disorders.
Table 1. 
Child/adolescent primary anxiety disorder and comorbidities.
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Anxiety disorders OAD (N = 35) MDD 
(N = 49)
ADHD (N = 70) ASD (N = 21) MD (N = 10) ODD/CD (N = 5) No disorder (N = 50)
F40.0—(AG) 1 (25%) 0 2 (50%) 0 0 0 1 (25%)
F40.1—(SOC) 4 (13.3%) 9 (30%) 10 (33.3%) 1 (3.3%) 1 (3.3%) 1 (3.3%) 4 (13.3%)
F40.2—(SPEC) 1 (6.7%) 1 (6.7%) 7 (46.7%) 3 (20%) 2 (13.3%) 0 1 (6.7%)
F40.8—(NOS) 2 (16.7%) 0 7 (58.3%) 0 0 0 2 (16.7%)
F40.9—(UNS) 0 0 1 (50%) 1 (50%) 0 0 0
F41.0—(PD) 1 (12.5%) 3 (37.5%) 0 0 1 (12.5%) 0 3 (37.5%)
F41.1—(GAD) 21 (24.1%) 22 (25.3%) 18 (20.7%) 9 (10.3%) 0 2 (2.2%) 14 (16.1%)
F41.2—(MAD) 3 (10.7%) 2 (7.1%) 8 (28.6%) 1 (3.6%) 0 1 (3.6%) 13 (45.4%)
F41.3—(OMAD) 1 (25%) 1 (25%) 1 (25%) 0 0 0 1 (25%)
F41.8—(OSA) 0 7 (31.8%) 3 (13.6%) 1 (4.5%) 3 (13.6%) 0 7 (31.8%)
F41.9—(ADU) 0 4 (44.4%) 1 (11.1%) 3 (33.3%) 0 0 1 (11.1%)
F93.0—(SAD) 1 (4.8%) 0 12 (57.1%) 2 (9.5%) 3 (14.3%) 1 (4.8%) 1 (4.8%)
F93.2—(SADC) 0 0 0 0 0 0 2 (100%)
Note: AG = agoraphobia; SOC = social phobias; SPEC = specific phobias; NOS = other phobic anxiety disorders; UNS = phobic anxiety disorder, unspecified; PD = panic disorder; GAD = generalized anxiety 
disorder; MAD = mixed anxiety and depressive disorder; OMAD = other mixed anxiety disorders; OSA = other specified anxiety disorders; ADU = anxiety disorder, unspecified; SAD = separation anxiety 
disorder of childhood; SADC = social anxiety disorder of childhood; OAD = other anxiety disorders; MDD = major depressive disorder; ADHD = attention deficit hyperactivity disorder; CD = conduct disorder; 
ASD = autism spectrum disorder; MR = mental retardation; ODD = oppositional defiant disorder.
Table 2. 
Comorbidity patterns by principal diagnosis [percentage].
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Anxiety 
disorders
Fluoxetine  
(N = 23)
Sertraline  
(N = 65)
Risperidone  
(N = 25)
Benzodiazepine  
(N = 38)
Other antipsychotics 
(N = 22)
Mood stabilizers 
(N = 18)
No pharmacological 
treatment (N = 116)
F40.0—(AG) 2 (50%) 1 (25%) 0 1 (25%) 0 0 1 (25%)
F40.1—(SOC) 2 (6.7%) 5 (16.7) 2 (6.7%) 2 (6.7%) 1 (3.3%) 0 21 (70%)
F40.2—(SPEC) 0 1 (6.7%) 3 (20%) 2 (13.3%) 1 (6.7%) 1 (6.7%) 10 (66.7%)
F40.8—(NOS) 0 4 (33.3%) 2 (16.7%) 1 (8.3%) 2 (16.6%) 5 (41.7%) 4 (33.3%)
F40.9—(UNS) 0 1 (50%) 0 0 0 0 1 (50%)
F41.0—(PD) 3 (37.5%) 4 (50%) 1 (12.5%) 4 (50%) 1 (12.5%) 0 0
F41.1—(GAD) 12 (13.8%) 30 (34.5%) 7 (8%) 19 (21.8%) 13 (14.9%) 6 (6.9%) 32 (36.8%)
F41.2—(MAD) 2 (7.1%) 7 (25%) 3 (10.7%) 1 (3.6%) 1 (3.6%) 4 (14.2%) 13 (46.4%)
F41.3—(OMAD) 0 0 0 1 (25%) 0 0 3 (75%)
F41.8—(OSA) 0 8 (36.4%) 3 (13.6%) 5 (22.7%) 2 (9%) 0 10 (45.5%)
F41.9—(ADU) 1 (11.1) 2 (22.2%) 2 (22.2%) 0 1 (11.1%) 0 4 (44.4%)
F93.0—(SAD) 1 (4.8%) 1 (4.8%) 2 (9.5%) 1 (4.8%) 0 0 17 (81%)
F93.2—(SADC) 0 1 (50%) 0 1 (50%) 0 2 (100%) 0
Note: AG = agoraphobia; SOC = social phobias; SPEC = specific phobias; NOS = other phobic anxiety disorders; UNS = phobic anxiety disorder, unspecified; PD = panic disorder; GAD = generalized anxiety 
disorder; MAD = mixed anxiety and depressive disorder; OMAD = other mixed anxiety disorders; OSA = other specified anxiety disorders; ADU = anxiety disorder, unspecified; SAD = separation anxiety 
disorder of childhood; SADC = social anxiety disorder of childhood.
Table 3. 
Pharmacological treatment patterns by principal diagnosis (percentage).
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adolescent girls it rises, being accountable for the significant difference between 
children and adolescents. For the comorbidity with MDD, the prevalence trends 
regarding age and sex are different than those for anxiety disorders. The comorbidity 
with MDD is rising with age, disregarding the gender, mentioning that the preva-
lence of MDD is higher in boys and the increase with age is milder than in girls.
There were no statistically significant relationships between the primary anxiety 
disorder diagnosis and gender. Regarding the comorbid diagnosis, the girls were more 
likely to receive an additional diagnosis of other anxiety disorder (18.4 vs. 10.8%), 
MDD (24.6 vs. 16.2%), while the boys were more likely to receive an additional 
diagnosis of ADHD (37.7 vs. 18.4%), ASD (12.3 vs. 4.4%), or MR (6.2 vs. 1.8%).
A chi-square analysis demonstrated that there was a significant difference in 
the presence of comorbidities between the principal diagnosis categories (chi-
square = 132.46; p = .08). The principal anxiety disorders diagnosis with a higher 
number of comorbidities were GAD, SOC, MAD, OSA, and SAD, as seen in Table 2. 
Comorbidities associated with anxiety disorders are very common, especially among 
them. Patients with anxiety disorders had also high rates of depression and ADHD.
About 92% of the children and 72.4% of the adolescents with a primary diagno-
sis of anxiety disorder had at least one comorbidity, underlining that in our sample, 
the children had more comorbidities than the adolescents. The pattern of comorbid-
ities was different for the most frequent anxiety disorders in our sample. For GAD, 
the most common comorbidities were other anxiety disorders and MDD, counting 
for almost half of the patients. Another 20.7% of them had comorbid ADHD. For 
MAD, the most frequent association was with ADHD, 28.6%, but the diagnosis 
includes specific symptoms of anxiety and depression, with neither type of symp-
tom severe enough to justify a diagnosis if considered separately, so symptoms of 
depression are necessary for diagnosis. For SOC, the most frequent comorbidities 
were ADHD and MDD (~30%), followed by other anxiety disorders. SAD, which is 
a diagnosis specific for children, had comorbid ADHD in 57.1% of the cases.
From the 70 patients with ADHD comorbid diagnosis, 20 (28.6%) were treated 
with atomoxetine and 10 (14.3%) with methylphenidate. One hundred twenty-
one (49.6%) patients in our sample didn’t receive pharmacological treatment, 49 
(55.7%) children and 72 (46.2%) adolescents, 65 (50%) boys and 56 (49.1%) girls 
(see Table 3). Seventy-five (30.7%) patients received only one medication, of which 
30 (34.1%) children and 45 (28.8%) adolescents, 41 (31.5%) boys and 34 (29.8%) 
girls. Forty-eight patients received more than one pharmacological treatment, of 
which 9 (10.2%) were children and 39 (25%) were adolescents, 24 (18.5%) boys and 
24 (21.1%) girls. There were no statistically significant relationships between the 
recommended treatment and gender, but there were significant differences regard-
ing the age group (children vs. adolescents). A chi-square analysis demonstrated 
that there was a significant difference in mono and without versus more pharma-
cological treatments between children and adolescent categories (chi-square = 7.77; 
p = .02), the adolescents being more likely to receive more medication.
3. Discussion and conclusions
Anxiety disorders are considered to be the most common psychiatric disorder in 
children and adolescents. In our study out of 2471 patients assessed and/or treated 
in the Clinic of Pediatric Psychiatry from Cluj-Napoca, Romania, between January 
and December 2017, only 244 (9.88%) patients received a primary diagnosis of 
different anxiety disorders, meaning that the anxiety disorders were the reason for 
admission. This low frequency of anxiety disorders in a clinical sample of children 
and adolescents can be explained by the selection criteria but also by the fact that 
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children internalization problems are less recognized by parents and referred for 
treatment. Merikangas et al. reported an overall prevalence of anxiety disorders 
with severe impairment and/or distress of 8.3%, which is close to the prevalence 
reported in our study [13]. In a meta-analysis of multiple data sets, Costello and 
Egger have found the prevalence of 10.2% for any AD, 5.4% for specific phobia 
(SPEC), 3.6% for social phobia (SOC), 2.6% for separation anxiety disorder (SAD), 
1.7% for generalized anxiety disorder (GAD), and 0.8% for panic disorder (PD) 
[15]. In our sample, the prevalences for these disorders were 35.6% for GAD, 12.3% 
for SOC, 8.6% for SAD, 6.1% for SPEC, and 3.3% for PD.
The study results showed that 79.5% of the selected sample had a comorbid 
disorder, and 34.4% had an anxiety or mood comorbidity which is similar to the 
findings from other studies on comorbidity rates of anxiety disorders in children. 
Previous studies found constantly elevated comorbidity rates in people with 
anxiety disorders [43], associated with increased symptom severity and greater 
functional impairment and worse outcome [15, 44]. The Child/Adolescent Anxiety 
Multimodal Study (CAMS) identified children and adolescents with social phobia, 
GAD, or SAD. They found that 78.6% of the sample had two or more of those 
disorders, and 35.9% met criteria for all three diagnoses simultaneously [36]. 
Kendall et al. find a comorbidity rate of 55.3% in a sample of youth with anxiety 
disorders [45]. Costello et al. found that comorbidity of AD with other psychiatric 
disorders was common, varying from 53% for GAD to 100% for SPEC. The most 
common type of comorbidity with non-anxiety disorders was with depression [15]. 
Also, the association between GAD and depression was found by Moffitt et al. in the 
Dunedin, New Zealand, longitudinal study with GAD predicting depression and 
depression predicting GAD across the life course [46]. In our study, 83.9% of the 
patients diagnosed with GAD had comorbidities, and 50% of them were diagnosed 
also with other anxiety disorder or depression.
Comorbidity patterns varied by ICD-10 diagnosis. The principal diagnoses asso-
ciated with significantly elevated risk for a comorbid diagnosis were GAD, MAD, 
SOC, OSA, and SAD. The association between GAD and other anxiety/depressive 
disorders raised many questions regarding the need for more accurate description 
in order to increase the reliability and validity of this disorder [47]. For SOC, the 
highest rate of comorbidities was with depression and ADHD. OSA had the highest 
comorbidity rate with depression, MAD with other anxiety disorders and ADHD 
and SAD with ADHD.
In our study, the prevalence of anxiety disorders primary diagnosis was 9.88%, 
with slightly different rates in females (46.7%) and males (53.3%). Although there 
were a greater number of boys than girls included in the study, the situation was 
different on age groups, more boys than girls in children group and more girls 
than boys in adolescent group; gender was not significantly associated with any of 
the anxiety diagnosis or comorbidity. The most common disorders in both males 
and females were GAD, SOC, MAD, other specified anxiety disorders (OSA), and 
separation anxiety disorder of childhood (SAD). Adolescents were more likely to 
receive a principal diagnosis of GAD or MAD than children. The prevalences of 
generalized anxiety disorder (GAD) and mixed anxiety and depressive (MAD) 
disorder were found higher in adolescents than in children (see Table 1), but 
with a higher prevalence in adolescent girls, the proportion of boys diagnosed 
with GAD and MAD being relatively stable with age. Children were more likely 
to receive a principal diagnosis of SPEC than adolescents. For specific phobias 
(SPEC), the prevalence was higher in children than in adolescents, but while the 
proportion of boys remained relatively stable, the diagnosis wasn’t present in 
adolescent girls. No significant differences by age were found for the other anxiety 
disorders.
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Different anxiety disorders have different age and gender distributions during 
childhood and adolescence. Separation anxiety disorder (SAD) and specific phobias 
(SPEC) are more common in children, while panic disorder and social phobia are 
more common in adolescents. Recent studies showed that, in the general popula-
tion, anxiety symptoms first decrease during early adolescence and subsequently 
increase from middle to late adolescence [22]. SAD and SPEC tend to emerge and 
predominate during childhood, whereas the initial onset of generalized anxiety 
disorder (GAD), panic disorder (PD), and social anxiety disorder (SAD) most often 
occurs during adolescence [24, 46].
According to the findings of our study, gender and age contributed to the pres-
ence of comorbidity. Adolescents were more likely than children to meet criteria for 
other anxiety disorder or MDD. The age and gender trends for these comorbidities 
were different. While for the comorbidity with other anxiety disorder, the preva-
lence in adolescent boys is decreasing; in adolescent girls, it rises, being accountable 
for the significant difference between children and adolescents. For the comorbidity 
with MDD, the prevalence trends regarding age and sex are different. The comor-
bidity with MDD is rising with age, disregarding the gender, mentioning that the 
prevalence of MDD is higher in boys and the increase with age is milder than in 
girls. The girls were more likely to receive an additional diagnosis of other anxiety 
disorder and MDD, while the boys were more likely to receive an additional diag-
nosis of ADHD, ASD, or MR. This pattern is consistent with other studies which 
have found either no difference between the sexes or greater rates of comorbidity in 
males [48]. When examined separately, no difference was found in the presence of 
comorbidity by sex, for the principal diagnoses, but there were significant differ-
ences by age. The fact that adolescents experience higher levels of comorbid depres-
sive disorders is consistent with findings from a clinical population [49].
Regarding the treatment patterns, in our study, the most frequently recom-
mended pharmacological treatment was SSRIs, 36% of the patients receiving 
fluoxetine or sertraline. Other recommended treatments were benzodiazepines 
recommended to 15.6% of the patients, antipsychotics recommended to 19.3%, and 
mood stabilizers recommended to 7.4% of them. About 49.6% of the patients in our 
sample did not receive pharmacological treatment, 30.7% patients received only 
one medication, and 19.7% received more than one pharmacological treatment. 
There were no statistically significant relationships between the recommended 
treatment and gender, but there were significant differences regarding the age 
group (children vs. adolescents), the adolescents being more likely to receive more 
medication. These results should be interpreted keeping in mind that the sample 
had a high rate of comorbidities (79.5%) and that the pharmacological treatment 
may target those disorders. There is some evidence that medication can be effective 
in treating anxiety in children and adolescents, at least on the short term. A recent 
meta-analysis showed anxiolytic medication to be associated with a significantly 
greater clinical response than placebo (58.1 vs. 31.5%). Selective serotonin reuptake 
inhibitors (SSRIs) are regarded as the pharmacological treatment of choice for anxi-
ety disorders in children and adolescents because of their effectiveness and safety 
profile. It is important to note that benzodiazepines have not been systematically 
assessed in children and adolescents, and, in view of concerns about dependency 
and side effects, their use is not recommended. It is unclear if there is an age below 
which medication would be contraindicated and what the duration of treatment 
should be [36]. Understanding the common patterns of anxiety disorders comor-
bidities and its treatments has important implications for child anxiety disorders 
treatment planning. Whether comorbid conditions might increase the need for 
treatment or cause patients to respond more poorly to psychological or psychiatric 
interventions is an important research area. Future treatments might need to be 
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adapted to better meet the needs of patients with commonly occurring comorbid 
conditions. This will help facilitate a better choice of existing treatments and may 
improve treatment outcomes.
It is important to consider the methodological limitations of the study which 
may impact the conclusions drawn based on this data. The age was considered 
within two categories, based on childhood and adolescence that can be seen as 
distinct developmental periods, and future studies should look at narrower age 
bands. Additionally, the sample included only admitted patients and excluded those 
receiving services in outpatient settings.
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